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Abstract A4 - Table 1 
Placebo (N=104) Acetaminophen (N=108) Glucosamine sulfate (N=106) 
Baseline 6 months Baseline 6 months Baseline 6 months 
Lequesne (points)a 10.8 (2.6) -1.9 (-2.6 to -1.2) 11.1 (2.7) -2.7 (-3.3 to -2.1) 11.0 (3.1) -3.1" (-3.8 to -2.3) 
WOMAC (points)a 37.9 (14.3) -8.2 (-11.3 to -5.1) 40.4 (14.8) -12.3 (-14.9 to -9.7) 38.3 (15.2) -12.91 (-15.6 to -10.1) 
OARSI-A responders (%) - 21.2% 33.3%~: 39.6%§ 
a Mean absolute (SD) at baseline and change (95%CI) at 6 months. P vs placebo: *0.032 [difference = -1.2 (-2.3 to -0.8)]; 10.039 [difference = -4.7 (-9.1 to -0.2)]; 
~:0.047; §0.007 
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Purpose: To define the role of Toll-like receptor(TLR) mediated 
signaling in the catabolic pathway in cultured human articular 
chondrocytes. 
Methods: Cartilage samples were obtained from OA and femur 
neck fracture patients and chondrocytes were cultured in both 
monolayer and explant. For evaluation of the expression of TLR 
in cartilage specimens, immunohistochemistry for TLR-2 and 4 
were performed. Regulation of TLR expression in cultured chon- 
drocytes was observed by RT-PCR. For stimulation of TLR2 and 
4, chondrocytes were treated with Staphylococcus aureus pep- 
tidoglycan(PGN) and liposaccharides (LPS), as TLR2 and 4 lig- 
ands, respectively. Production of MMP-1,3, 13 and prostaglandin 
(PG) E2 was evaluated by ELISA assay. Production of nitric ox- 
ide (NO) was analyzed by Griess reaction. Phosphorylation of 
JNK and NF-kB activation were observed with Western blot and 
electrophoretic mobility shift assay, respectively. 
Results: Expression of TLR 2, and 4 was upregulated in lesion 
area of OA cartilage. Treatment with interleukin-1, tumor necro- 
sis factor-alpha, PGN and LPS all significantly upregulated both 
TLR2 and TLR4 expression in cultured chondrocytes. Production 
of MMP-1, 3, and 13, NO and PGE2 significantly increased af- 
ter treating chondrocytes with either PGN or LPS, which was 
inhibited by anti-TLR antibodies. Treatment with PGN and LPS 
led to phosphorylation of JNK and activation of NF-kB. Pretreat- 
ment of chondrocytes with JNK inhibitor SP600125 and NF-kB 
inhibitor, MG132 led to significant downregulation of all catabolic 
responses mediated by TLR ligands. 
Conclusion: TLR ligands function as stimulants of chondrocyte 
catabolism. TLR mediated signaling may play an important role in 
the cartilage degradation in rheumatoid and osteoarthritis. Eluci- 
dation of endogenous TLR ligands working as a catabolic stimuli 
on chondorcytes is the subject of further research. 
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Aim of Study: Two multicenter, randomised, placebo-controlled, 
double-blind trials lately investigated the efficacy of oral glu- 
cosamine in knee osteoarthritis (OA), using a symptomatic med- 
ication as reference: GAIT performed by the NIH in the US with 
nutraceutical glucosamine hydrochloride 500 mg t.i.d, vs cele- 
coxib, and GUIDE performed in Europe with the prescription 
glucosamine sulfate (GS) 1500 mg once-a-day (u.i.d.) vs ac- 
etaminophen, i.e. the preferred symptomatic medication in OA 
practice guidelines. We report the results of GUIDE. 
Methods: 318 patients (88% women) with knee OA (ACR crite- 
ria) were randomised to double-dummy oral GS soluble powder 
1500 mg u.i.d., or acetaminophen 1000 mg tablets t.i.d. (3 g/day, 
as recommended in Europe), or placebo for 6 months. The res- 
cue medication consisted of standardised use of ibuprofen 400 
mg tablets (daily diary recording). The primary efficacy parame- 
ter was the ITT 6-month change in the Lequesne index, using the 
LOCF approach for patients not completing the study according 
to the protocol (34 on placebo, 28 in each the acetaminophen 
and GS groups, without differences in drop-out reasons). Sec- 
ondary efficacy parameters included the WOMAC index and the 
OARSI-A responder criteria. Analysis on the indexes was per- 
formed by GLM-ANOVA, with Dunnett's pairwise comparisons vs 
placebo. The proportions of responders and patients using the 
rescue medication were compared by the chi-square test. 
Results: The groups were comparable for demographics and 
baseline disease characteristics. GS efficacy vs placebo was sig- 
nificant on all parameters (Table 1). Acetaminophen had more 
responders than placebo, but it failed to reach a significant differ- 
ence on the Lequesne (p=0.18) and WOMAC (p=0.077) indexes. 
More patients on placebo used the rescue medication (p=0.027 
and 0.045 vs GS and acetaminophen, respectively). There were 
no differences among groups in safety. 
Conclusions: Glucosamine sulfate at the oral once-daily dose of 
1500 mg might be the preferred symptomatic medication in knee 
OA. 
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Aim of Study: Subchondral trabecular bone loss is character- 
istic of progressive knee OA (Messent et al, Osteoarthritis Cart 
2005;13:463-70). This study determined whether risedronate, a 
bisphosphonate, slowed this loss of bone within the proximal tibia 
of patients with medial compartment disease. 
Methods: 100 patients were randomly selected from each treat- 
ment group (each N~300) comprising placebo, and risedronate 
5mg qd, 15mg qd and 50mg qwk from a large double blind, mul- 
ticenter, placebo-controlled 2-year investigation of patients with 
knee OA, joint space width (JSW) between 2-4 mm, at least one 
osteophyte present and knee pain most days of 1 month in last 
$14 Pod ium Presentat ions  
3. Using fluoroscopic semi-flexed x-ray technique of Buckland- 
Wright, baseline and exit knee radiographs were digitised by laser 
scanner. Based upon computerized measurement of minimum 
medial compartment JSW, each group was subdivided into those 
with non-progressive or progressive joint space narrowing (JSN), 
viz. JSN _>0.6 mm at any point post-baseline (placebo n=l 1 ; 5mg 
n=16; 15mg n=21; 50mg n=17). The complement of this group 
forms the non-progressors. A region of interest (3/4 width of tib- 
ial compartment x 6mm height) was selected in the medial com- 
partment. Computerised method of Fractal Signature Analysis 
(FSA) quantified longitudinal changes in number and thickness 
(Buckland-Wright et al. Calcif Tissue Int 1994;54:106-12) sepa- 
rately in horizontal and vertical trabecular organisation in all study 
knees. 
Results: Over the study period, most knees had a slight de- 
crease in FSA of vertical and horizontal trabeculae (size range: 
0.18 to 1.14 mm), consistent with a modest decrease in tra- 
becular number. However, compared to the non-progressor JSN 
group the degree of bone loss was substantially greater in knees 
with progressive JSN (p<0.05) in both placebo and 5mg groups 
for vertical (placebo, sizes: 0.72-0.84mm, 1.14mm), (5mg, size: 
0.54mm) and horizontal (5mg, sizes: 0.30-0.66mm) trabeculae 
respectively, than those in 15mg and 50mg groups. In the lat- 
ter, the progressive JSN group did not show trabecular loss apart 
from mild horizontal trabeculae change within the 15mg group 
(sizes: 0.36-0.42mm, 0.72-0.90mm) only. 
Conclusion: In knee OA high doses of risedronate reduced the 
loss of trabecular structure within the subarticular egion of the 
medial diseased compartment. In contrast, patients with progres- 
sive JSN administered placebo or 5mg risedronate did not show 
a trabecular bone benefit in this highly aggressive disease sub- 
set. Thus, despite progressive cartilage loss, higher doses of rise- 
dronate protected joints against aggressive trabecular bone loss, 
thereby preserving its structural integrity, delaying the onset of 
compartmental collapse and potentially the requirement for knee 
arthroplasty. 
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Background: Type II collagen (CII) is the most abundant pro- 
tein of cartilage matrix. The synthesis and degradation of CII can 
be assessed by measuring the serum concentration of the N- 
propeptide of collagen type IIA (PIIANP) and the urinary excre- 
tion of crosslinked C-telopeptide (CTX-II), respectively. Previous 
short-term studies in advanced OA have shown that baseline lev- 
els of serum PIIANP and CTX-II were associated with disease 
progression. The aim of this study was to investigate the longi- 
tudinal changes of serum PIIANP and urinary CTX-II and their 
relationships with radiological progression in patients with early 
OA followed prospectively for 5 years. 
Patients and methods: Eighty four patients with persistent pain 
(>3 months) in one or both knees were included (54% female, 
mean age; 62 yr; 39% presenting a Kellgren-Lawrence score <2). 
We measured PIIANP and CTX-II using specific ELISAs at base- 
line, 2 yr, 3 yr and 5 yr and knee radiographs were obtained at 
baseline and 5 years. Disease progression was defined as either 
a reduction in the tibiofemoral joint space by at least 2 mm or total 
knee replacement at either knee during the 5-year follow-up. 
Results: During the 5 yr of the study there was a slight but sig- 
nificant increase of PIIANP (mean: 1.6%/yr, p<0.0001 ), whereas 
urinary CTX-II remained stable. Both serum PIIANP and urinary 
CTX-II were significantly higher throughout he study in the 24 
progressors compared to the 60 non progressors (p <0.05 for 
both by ANOVA). When patients were classified in quartile of 
mean-5yr levels of PIIANP or CTX-II, the increase in the risk of 
progression was observed in the highest quartile of PIIANP and 
for the two highest quartiles (above median) for CTX-II. The table 
below shows the odds-ratio, the sensitivity and specificity of pro- 
gression for patients with PIIANP in the highest quartile, CTX-II 
above the median or the combination of both markers. 
PIIANP alone CTX-II alone PIIANP+CTX-II 
Odds-ratio 3.2, p=O.O3 3.4, p=O.O2 11.8, p=O.OO2 
(95% CI) (1.1-9.0) (1.2-9.4) (2.5-54.5) 
Sensitivity (%) 42 71 92 
Sensitivity (%) 82 58 52 
Conclusion: In conclusion, in early knee OA, disease progres- 
sion is associated with increases of both synthesis and degrada- 
tion of type II collagen. Combination of serum PIIANP and urinary 
CTX-II may be useful to improve the identification of patients with 
early knee OA at high risk for rapid progression. 
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Purpose: As osteoarthritis (OA) is usually polyarticular, 
biomarker correlations with multiple, as opposed to single, joint 
radiologic scores are essential. We developed an assessment 
tool of OA burden (TQOL) using weighted scoring measures of 
large joint involvement, to correlate TQOL scores with biomark- 
ers of cartilage synthesis and degradation. 
Methods: X-rays and sera from 19 subjects (3 families in a hered- 
itary OA study); median age 34 years (range 12-70 yrs). X-rays of 
hands, hips and knees were read blind by 2 readers and scored 
for K-L grade 0-IV, and 0-111 (where grade 1 was considered 0 
to enhance linearity); osteophytes (OP) (0-3); joint space nar- 
rowing (JSN) (0-3); and sclerosis (0/1). Using MRI-derived car- 
tilage volumes from a normal control population, X-ray scores 
were weighted as follows: knee cartilage sagittal vol 22 ml or 
unicompartmental (UC) 11 ml; coronal weight-bearing 7 ml or 
UC 3.5 ml; hip total cartilage vol 9 ml; superior or medial-axial 
4.5 ml. Hand cartilage vol (approx. 2 ml) contributed minimally 
and was not included. TQOL scores were calculated for 4 large 
joints as: [(knee vols)(K-L grade, or JSN or sclerosis or OP) + 
(hip vols)(K-L grade or JSN or sclerosis or OP)]. Total cartilage 
vol at risk was 62 ml. Biomarkers included cartilage oligomeric 
protein (COMP), bone sialoprotein (BSP), neoepitope 846, type 
II collagen propeptide(C-II ProP) and 7H3 as measures of pro- 
teoglycan (PG) and collagen synthesis and degradation, bone 
synthesis and matrix turnover. Pearson correlation coefficients 
were calculated for each biomarker elated to the TQOL scores 
and also using only the radiographically worse knee to simulate 
single-joint-derived versus TQOL-derived calculations. 
Results: Significant correlations were found between neoepitope 
846 and C-II ProP, markers of PG and collagen synthesis respec- 
